首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2103054

全球腫瘤領域許可與合作分析：2026 年

Global Oncology Licensing & Partnerships Analysis, 2026

出版日期: 2026年07月23日 | 出版商:

Knowledge Sourcing Intelligence | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

腫瘤學仍然是全球生命科學產業最活躍的治療領域之一，在研發投資、臨床試驗、許可和策略合作方面佔據了相當大的佔有率。癌症生物學的複雜性，以及人們對精準醫療、免疫療法、細胞療法、基因療法和標靶治療的日益關注，促使企業透過許可協議和合作研究協議尋求外部創新。隨著腫瘤藥物研發成本和風險的不斷攀升，合作正成為取得創新技術、拓展產品平臺和加速市場准入的重要策略。

許可和合作活動在整個腫瘤價值鏈中發揮著至關重要的作用。早期生技公司通常依靠策略合作來獲得資金籌措、研發技術和商業化能力，而大型製藥企業利用合作來強化其產品組合、獲取新興技術並拓展其在多種癌症適應症中的治療範圍。隨著基於生物標記的療法和個人化醫療的重要性日益凸顯，腫瘤領域對合作創新模式的需求也變得更加迫切。

市場促進因素

擴大癌症藥物開發平臺

市場成長的主要驅動力之一是全球癌症治療產品線的持續擴張。製藥和生物技術公司正在開發多種療法，包括免疫療法、抗體藥物複合體（ADC）、細胞療法、基因療法、放射性藥物和定向小分子化合物。

隨著研發專案變得越來越專業化和技術複雜化，企業越來越傾向於尋求授權協議和策略合作夥伴關係，以利用其創新資產和科學專長。

對外部創新日益成長的需求

為了補充自身內部研發能力，製藥業正日益採用外部創新策略。授權協議使企業能夠利用有前景的候選藥物、新型治療平台、專有技術和專業研發知識。

這一趨勢在癌症領域尤其明顯，因為快速的科學進展要求各機構不斷擴大和豐富其研究組合。

精準腫瘤學的興起

精準醫療透過針對特定基因突變、生物標記和分子特徵量身定做治療方案，徹底改變了癌症治療。開發個人化癌症療法通常需要診斷、基因組學、人工智慧和伴隨診斷方面的專業知識。

因此，各公司正在整合各自的互補技術，並建立策略合作夥伴關係，以加速標靶癌症療法的開發。

研發支出增加

癌症治療藥物的研發需要大量投資，這也是推動合作創業模式應用的主要因素。臨床試驗、監管合規、生產設施建設和商業化活動都需要大量資金。

許可和合作協議有助於公司分擔風險、最佳化資源配置，並提高產品開發和商業化的成功機率。

本報告研究了全球腫瘤領域的許可和合作趨勢，總結了疾病概況、市場影響因素、按治療領域和開發階段等各種類別分類的許可和合作趨勢、授權合約和合作收入預測、區域/主要國家趨勢、競爭格局、主要公司概況以及未來展望。

腫瘤領域授權模式概述
腫瘤學領域的合作類型
- 共同開發契約
- 聯合商業化協議
- 研究夥伴關係
- 合資
- 技術授權合約
- 製造合作夥伴關係
交易結構分析
- 合約獎金
- 里程碑付款
- 特許權使用費協議
- 股票投資
- 利潤分享模式
許可趨勢：按治療領域分類
- 免疫腫瘤學
- 分子標靶治療
- 細胞療法
- 抗體藥物複合體（ADC）
- 利用放射性藥物治療癌症
合作關係趨勢：依發展階段分類
- 發現階段
- 臨床前階段
- 第一階段
- 第二階段
- 第三階段
- 商業舞台
跨國合作趨勢
產學合作
創業投資與新創企業合作的趨勢
策略聯盟案例研究

第5章：創新與通路聯繫分析

管道合作夥伴關係概述
癌症治療藥物合作開發趨勢
生物標記和伴隨診斷領域的合作
人工智慧和數位癌症領域的合作
細胞和基因治療領域的策略夥伴關係
ADC聯合發展趨勢
聯合治療中的合作
雙特異性抗體領域的合作趨勢
新興模式領域的夥伴關係
未來值得關注的創新領域

第6章：治療和商業化的現狀

癌症治療現狀
癌症領域的商業化模式
精準醫療的商業化策略
伴隨診斷整合
市場進入和贖回的合作夥伴關係
分銷和商業化合作夥伴關係
生命週期管理策略
專利和專有權方面的考慮

第7章市場規模及預測

全球腫瘤產品授權市場概覽
過往交易活動的分析
市場預測方法
預測授權合約數量
基於合作關係的收入預測
按治療區域進行的預測
按發展階段預測
按合夥類型預測
區域預測
未來投資展望

第8章市場區隔分析

按合夥類型
- 授權協議
- 共同開發契約
- 聯合商業化協議
- 研究夥伴關係
- 合資
- 製造合作夥伴關係
按治療區域
- 免疫腫瘤學
- 分子標靶治療
- 細胞療法
- 基因治療
- 抗體藥物複合體（ADC）
- 利用放射性藥物治療癌症
按發展階段
- 發現階段
- 臨床前階段
- 第一階段
- 第二階段
- 第三階段
- 市售產品
最終用戶
- 製藥公司
- 生技公司
- 學術和研究機構
- CRO

第9章區域分析

北美洲
歐洲
亞太地區
拉丁美洲
中東和非洲
- 許可活動概述
- 投資趨勢
- 法規環境
- 競爭性推薦的現狀

第10章：主要國家分析

加拿大
德國
中國
日本
印度

第11章法規與政策概述

與癌症領域合作相關的全球法規
FDA針對腫瘤領域合作的法律規範
EMA的法律規範
PMDA的法律規範
CDSCO的法律規範
國家藥品管理局法律規範
智慧財產權和專利相關法規
反壟斷和競爭法方面的考量
資料共用和合規要求
未來監理趨勢

第12章競爭格局

腫瘤領域主要公司的合作策略
競爭性標竿分析
授權合約的比較分析
策略聯盟分析
投資和資金籌措基準分析
併購和合作活動
新興癌症領域新創公司
主要公司的SWOT分析

第13章：公司簡介

Roche
Merck & Co.
Bristol Myers Squibb
AstraZeneca
Pfizer
Novartis
Johnson & Johnson Innovative Medicine
Gilead Sciences
Eli Lilly and Company
Amgen

第14章未來展望

腫瘤學領域合作的未來
擴大精準腫瘤學領域的合作
人工智慧與數位健康的融合
細胞和基因治療許可的未來
聯合治療中合作的演變
未來投資環境
策略建議

第15章：調查方法

簡介目錄

Product Code: KSI-008850

Oncology remains one of the most active therapeutic areas in the global life sciences industry, accounting for a substantial share of research and development investments, clinical trials, licensing agreements, and strategic partnerships. The complexity of cancer biology, combined with the growing emphasis on precision medicine, immunotherapy, cell therapy, gene therapy, and targeted treatments, has encouraged companies to seek external innovation through licensing transactions and collaborative agreements. As the cost and risk associated with oncology drug development continue to rise, partnerships have become an increasingly important strategy for accessing innovative technologies, expanding product pipelines, and accelerating market entry.

Licensing and partnership activities play a critical role throughout the oncology value chain. Early-stage biotechnology companies often rely on strategic collaborations to secure funding, development expertise, and commercialization capabilities, while larger pharmaceutical organizations use partnerships to strengthen portfolios, access emerging technologies, and expand therapeutic coverage across multiple cancer indications. The growing importance of biomarker-driven treatments and personalized medicine is further increasing the need for collaborative innovation models within the oncology sector.

Market Drivers

Expanding Oncology Drug Development Pipeline

One of the primary drivers of market growth is the continuous expansion of the global oncology drug pipeline. Pharmaceutical and biotechnology companies are developing therapies across a wide range of modalities, including immunotherapies, antibody-drug conjugates, cell therapies, gene therapies, radiopharmaceuticals, and targeted small molecules.

As development programs become more specialized and technologically complex, companies increasingly pursue licensing agreements and strategic partnerships to access innovative assets and scientific expertise.

Growing Demand for External Innovation

The pharmaceutical industry is increasingly adopting external innovation strategies to supplement internal research capabilities. Licensing agreements allow companies to gain access to promising drug candidates, novel therapeutic platforms, proprietary technologies, and specialized research capabilities.

This trend is particularly evident in oncology, where rapid scientific advancements require organizations to continuously expand and diversify their research portfolios.

Rise of Precision Oncology

Precision medicine has transformed cancer treatment by enabling therapies tailored to specific genetic mutations, biomarkers, and molecular profiles. The development of personalized oncology therapies often requires expertise in diagnostics, genomics, artificial intelligence, and companion diagnostics.

As a result, companies are forming strategic alliances to integrate complementary technologies and accelerate the development of targeted cancer treatments.

Increasing Research and Development Costs

The high cost of oncology drug development continues to encourage collaborative business models. Clinical trials, regulatory requirements, manufacturing investments, and commercialization activities require substantial financial resources.

Licensing and partnership agreements help companies share risks, optimize resource allocation, and improve the likelihood of successful product development and commercialization.

Market Restraints

Complex Negotiation and Deal Structures

Oncology licensing agreements often involve complex financial arrangements, milestone payments, royalty structures, territorial rights, intellectual property considerations, and development responsibilities.

Negotiating these agreements can be time-consuming and may delay partnership execution.

Regulatory and Intellectual Property Challenges

Differences in regulatory requirements across regions can complicate partnership strategies and commercialization plans. Intellectual property disputes, patent challenges, and exclusivity concerns may also create uncertainty for participating organizations.

Managing these issues requires substantial legal, regulatory, and strategic expertise.

High Development Risk

Despite strong scientific advances, oncology drug development remains associated with significant clinical and regulatory risk. Many investigational therapies fail during clinical development, potentially affecting the value and success of licensing agreements.

Companies must carefully evaluate scientific data, commercial potential, and competitive dynamics before entering strategic partnerships.

Technology and Segment Insights

The global oncology licensing and partnerships analysis market can be segmented by deal type, therapy modality, cancer indication, stage of development, partner type, and geography.

By deal type, the market includes licensing agreements, co-development partnerships, co-commercialization agreements, research collaborations, joint ventures, asset acquisitions, technology licensing, distribution agreements, and strategic alliances. Licensing agreements account for a significant share of market activity due to their ability to provide access to innovative drug candidates and proprietary technologies.

By therapy modality, the market includes immunotherapy, targeted therapy, antibody-drug conjugates, cell therapy, gene therapy, cancer vaccines, radiopharmaceuticals, small molecule therapies, and combination therapies. Immunotherapy and targeted therapy segments continue to attract substantial partnership activity due to their strong clinical and commercial potential.

By cancer indication, the market includes lung cancer, breast cancer, colorectal cancer, prostate cancer, hematological malignancies, gastric cancer, liver cancer, ovarian cancer, pancreatic cancer, skin cancer, and other oncology indications. Lung and breast cancer remain among the most active areas for licensing transactions because of their large patient populations and extensive research activity.

By stage of development, the market includes discovery-stage assets, preclinical candidates, Phase I programs, Phase II programs, Phase III assets, and commercial-stage products. Early-stage and mid-stage assets represent significant partnership opportunities as larger organizations seek to secure future growth through access to innovative technologies.

By partner type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, research organizations, contract research organizations, and healthcare technology companies. Pharmaceutical and biotechnology companies account for the majority of licensing and partnership transactions due to their active involvement in oncology research and commercialization.

Technological advancements continue to shape partnership activity across the oncology ecosystem. Artificial intelligence, machine learning, genomic sequencing, biomarker discovery platforms, companion diagnostics, digital pathology, and real-world evidence analytics are creating new opportunities for collaboration. Companies increasingly seek partnerships that combine therapeutic development with diagnostic capabilities and data-driven healthcare solutions.

The growing integration of artificial intelligence into drug discovery and clinical development is also driving partnership activity as pharmaceutical companies seek access to advanced computational platforms that improve target identification, patient selection, and clinical trial efficiency.

Geographically, North America dominates the market due to its strong biotechnology ecosystem, extensive venture capital investment, advanced research infrastructure, and concentration of leading pharmaceutical companies. Europe maintains a significant position supported by robust research institutions, innovation clusters, and collaborative healthcare initiatives. Asia-Pacific is expected to witness strong growth owing to expanding biotechnology sectors, increasing research investments, growing clinical trial activity, and rising participation in global licensing transactions. Latin America and the Middle East & Africa are gradually increasing their involvement in oncology research collaborations and technology partnerships.

Competitive and Strategic Outlook

The competitive landscape is characterized by continuous deal-making activity among pharmaceutical companies, biotechnology firms, academic institutions, and emerging technology providers. Organizations are increasingly focused on securing access to innovative therapeutic platforms, next-generation oncology technologies, and differentiated clinical assets.

Strategic partnerships have become essential for maintaining competitive positioning in a rapidly evolving oncology market. Companies are utilizing licensing agreements to strengthen product pipelines, expand geographic reach, access novel technologies, and accelerate commercialization timelines. Collaborative development models are becoming increasingly common as organizations seek to reduce risk and improve development efficiency.

Mergers, acquisitions, co-development partnerships, and cross-border licensing transactions are expected to remain important strategic tools for companies seeking growth within the oncology sector. As scientific innovation continues to accelerate, demand for high-quality oncology assets and partnership opportunities is expected to remain strong throughout the forecast period.

Conclusion

The global oncology licensing and partnerships analysis market is poised for sustained growth through 2031, supported by expanding oncology drug pipelines, increasing reliance on external innovation, growing precision medicine adoption, and rising investment in advanced cancer therapies. Strategic collaborations are becoming increasingly important for addressing the scientific, financial, and regulatory complexities associated with oncology drug development. While challenges related to deal complexity, intellectual property management, and development risk remain, ongoing advancements in biotechnology, genomics, artificial intelligence, and personalized medicine are expected to create substantial opportunities for licensing and partnership activity across the global oncology ecosystem.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Report Overview
1.2 Scope of the Report
1.3 Definition of Oncology Licensing & Partnerships
1.4 Key Findings
1.5 Strategic Partnership Trends in Oncology
1.6 Key Deal Structures and Collaboration Models
1.7 Investment and Innovation Outlook
1.8 Analyst Recommendations

2. Oncology Industry Overview

2.1 Introduction to the Oncology Market
2.2 Evolution of Oncology Drug Development
2.3 Role of Strategic Partnerships in Oncology Innovation
2.4 Oncology Value Chain Analysis
2.5 Precision Oncology and Biomarker Integration
2.6 Immuno-Oncology Market Evolution
2.7 Cell & Gene Therapy Expansion in Oncology
2.8 Emerging Oncology Technology Platforms

3. Market Dynamics

3.1 Market Drivers
- 3.1.1 Increasing R&D Costs in Oncology
- 3.1.2 Rising Demand for Precision Medicine
- 3.1.3 Expansion of Immuno-Oncology Collaborations
- 3.1.4 Growth in Cell & Gene Therapy Partnerships
3.2 Market Restraints
- 3.2.1 Intellectual Property Challenges
- 3.2.2 High Clinical Development Failure Rates
- 3.2.3 Regulatory and Compliance Complexity
- 3.2.4 Commercialization Risk Sharing Challenges
3.3 Market Opportunities
- 3.3.1 ADC Licensing Expansion
- 3.3.2 AI-Driven Oncology Drug Discovery Collaborations
- 3.3.3 Cross-Border Biopharma Partnerships
- 3.3.4 Companion Diagnostic Partnerships
3.4 Market Challenges
- 3.4.1 Valuation Disputes in Licensing Agreements
- 3.4.2 Clinical Trial Coordination Complexity
- 3.4.3 Manufacturing and Supply Chain Integration
- 3.4.4 Competitive Partnership Saturation
3.5 Porter's Five Forces Analysis
3.6 PESTLE Analysis
3.7 Investment & Funding Trends
3.8 Mergers & Acquisitions Analysis

4. Licensing & Partnership Landscape

4.1 Overview of Oncology Licensing Models
4.2 Types of Oncology Partnerships
- 4.2.1 Co-development Agreements
- 4.2.2 Co-commercialization Agreements
- 4.2.3 Research Collaborations
- 4.2.4 Joint Ventures
- 4.2.5 Technology Licensing Agreements
- 4.2.6 Manufacturing Partnerships
4.3 Deal Structure Analysis
- 4.3.1 Upfront Payments
- 4.3.2 Milestone-Based Payments
- 4.3.3 Royalty Agreements
- 4.3.4 Equity Investments
- 4.3.5 Profit-Sharing Models
4.4 Licensing Trends by Therapy Area
- 4.4.1 Immuno-Oncology
- 4.4.2 Targeted Therapy
- 4.4.3 Cell Therapy
- 4.4.4 Antibody-Drug Conjugates
- 4.4.5 Radiopharmaceutical Oncology
4.5 Partnership Trends by Development Stage
- 4.5.1 Discovery Stage
- 4.5.2 Preclinical Stage
- 4.5.3 Phase I
- 4.5.4 Phase II
- 4.5.5 Phase III
- 4.5.6 Commercial Stage
4.6 Cross-Border Collaboration Trends
4.7 Academic-Industry Collaborations
4.8 Venture Capital and Startup Partnership Trends
4.9 Strategic Alliance Case Studies

5. Innovation & Pipeline Collaboration Analysis

5.1 Pipeline Collaboration Overview
5.2 Collaborative Oncology Drug Development Trends
5.3 Biomarker and Companion Diagnostic Partnerships
5.4 AI and Digital Oncology Collaborations
5.5 Cell & Gene Therapy Strategic Alliances
5.6 ADC Co-development Trends
5.7 Combination Therapy Partnerships
5.8 Bispecific Antibody Collaboration Trends
5.9 Emerging Modality Partnerships
5.10 Future Innovation Hotspots

6. Treatment & Commercialization Landscape

6.1 Current Oncology Treatment Landscape
6.2 Commercialization Models in Oncology
6.3 Precision Medicine Commercial Strategy
6.4 Companion Diagnostics Integration
6.5 Market Access and Reimbursement Collaboration
6.6 Distribution and Commercial Partnerships
6.7 Lifecycle Management Strategies
6.8 Patent and Exclusivity Considerations

7. Market Size & Forecast

7.1 Global Oncology Licensing Market Overview
7.2 Historical Deal Activity Analysis
7.3 Market Forecast Methodology
7.4 Licensing Deal Volume Forecast (2026-2035)
7.5 Partnership Revenue Forecast
7.6 Forecast by Therapy Area
7.7 Forecast by Development Stage
7.8 Forecast by Partnership Type
7.9 Forecast by Region
7.10 Future Investment Outlook

8. Market Segmentation

8.1 By Partnership Type
- 8.1.1 Licensing Agreements
- 8.1.2 Co-development Agreements
- 8.1.3 Co-commercialization Agreements
- 8.1.4 Research Collaborations
- 8.1.5 Joint Ventures
- 8.1.6 Manufacturing Partnerships
8.2 By Therapy Area
- 8.2.1 Immuno-Oncology
- 8.2.2 Targeted Therapy
- 8.2.3 Cell Therapy
- 8.2.4 Gene Therapy
- 8.2.5 Antibody-Drug Conjugates
- 8.2.6 Radiopharmaceutical Oncology
8.3 By Development Stage
- 8.3.1 Discovery Stage
- 8.3.2 Preclinical Stage
- 8.3.3 Phase I
- 8.3.4 Phase II
- 8.3.5 Phase III
- 8.3.6 Commercialized Products
8.4 By End User
- 8.4.1 Pharmaceutical Companies
- 8.4.2 Biotechnology Companies
- 8.4.3 Academic & Research Institutes
- 8.4.4 Contract Research Organizations

9. Geographical Analysis

9.1 North America
- 9.1.1 Licensing Activity Overview
- 9.1.2 Investment Trends
- 9.1.3 Regulatory Environment
- 9.1.4 Competitive Partnership Landscape
9.2 Europe
- 9.2.1 Licensing Activity Overview
- 9.2.2 Investment Trends
- 9.2.3 Regulatory Environment
- 9.2.4 Competitive Partnership Landscape
9.3 Asia-Pacific
- 9.3.1 Licensing Activity Overview
- 9.3.2 Investment Trends
- 9.3.3 Regulatory Environment
- 9.3.4 Competitive Partnership Landscape
9.4 Latin America
- 9.4.1 Licensing Activity Overview
- 9.4.2 Investment Trends
- 9.4.3 Regulatory Environment
- 9.4.4 Competitive Partnership Landscape
9.5 Middle East & Africa
- 9.5.1 Licensing Activity Overview
- 9.5.2 Investment Trends
- 9.5.3 Regulatory Environment
- 9.5.4 Competitive Partnership Landscape

10. Key Countries Analysis

10.1 United States
- 10.1.1 Licensing Deal Activity
- 10.1.2 Oncology Innovation Ecosystem
- 10.1.3 FDA Regulatory Environment
- 10.1.4 Key Partnership Trends
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Global Oncology Collaboration Regulations
11.2 FDA Regulatory Framework for Oncology Partnerships
11.3 EMA Regulatory Framework
11.4 PMDA Regulatory Framework
11.5 CDSCO Regulatory Framework
11.6 NMPA Regulatory Framework
11.7 Intellectual Property & Patent Regulations
11.8 Antitrust and Competition Considerations
11.9 Data Sharing and Compliance Requirements
11.10 Future Regulatory Trends

12. Competitive Landscape

12.1 Leading Oncology Partnership Strategies
12.2 Competitive Benchmarking
12.3 Licensing Deal Comparison Analysis
12.4 Strategic Alliance Analysis
12.5 Investment and Funding Benchmarking
12.6 M&A and Partnership Activity
12.7 Emerging Oncology Startups
12.8 SWOT Analysis of Leading Players

13. Company Profiles

13.1 Roche
- 13.1.1 Oncology Partnership Strategy
- 13.1.2 Key Licensing Agreements
- 13.1.3 Companion Diagnostic Collaborations
- 13.1.4 ADC and Immuno-Oncology Alliances
13.2 Merck & Co.
- 13.2.1 Immuno-Oncology Collaborations
- 13.2.2 Keytruda Partnership Strategy
- 13.2.3 Combination Therapy Alliances
- 13.2.4 Clinical Development Collaborations
13.3 Bristol Myers Squibb
- 13.3.1 Cell Therapy Collaborations
- 13.3.2 Licensing and Acquisition Strategy
- 13.3.3 Hematology Partnership Portfolio
13.4 AstraZeneca
- 13.4.1 ADC Partnership Strategy
- 13.4.2 Precision Oncology Collaborations
- 13.4.3 Global Licensing Expansion
13.5 Pfizer
- 13.5.1 Oncology Licensing Strategy
- 13.5.2 Targeted Therapy Collaborations
- 13.5.3 Commercialization Partnerships
13.6 Novartis
- 13.6.1 Cell & Gene Therapy Alliances
- 13.6.2 Radioligand Therapy Partnerships
- 13.6.3 Strategic Investment Analysis
13.7 Johnson & Johnson Innovative Medicine
- 13.7.1 Hematology Oncology Collaborations
- 13.7.2 Licensing and Co-development Strategy
- 13.7.3 Commercial Expansion Initiatives
13.8 Gilead Sciences
- 13.8.1 Cell Therapy Partnership Ecosystem
- 13.8.2 Kite Pharma Collaboration Strategy
- 13.8.3 Manufacturing Alliances
13.9 Eli Lilly and Company
- 13.9.1 Precision Oncology Collaborations
- 13.9.2 Licensing Expansion Strategy
- 13.9.3 Biomarker Partnership Analysis
13.10 Amgen
- 13.10.1 Bispecific Antibody Collaborations
- 13.10.2 Strategic Oncology Partnerships
- 13.10.3 Clinical Development Alliances